Compare ADMA Biologics Inc (ADMA) vs American Tower Corp (AMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs American Tower Corp — how do they compare? ADMA Biologics Inc trades at $9.21 (market cap $2.13B), while American Tower Corp trades at $165.82 (market cap $76.99B). The key difference: American Tower Corp is far larger — about 36.1× ADMA Biologics Inc's market cap, and American Tower Corp pays a 4.22% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AMT | |
|---|---|---|
Market Cap | $2.13B | $76.99B |
Sector | Health | Real Estate |
52-Week High | $20.38 | $232.35 |
52-Week Low | $7.60 | $162.11 |
Enterprise Value | $2.20B | $120.51B |
Dividend Yield | — | 4.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AMT trades at $165.25, down 0.47% on the day, with a bearish technical signal from moving averages and oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Strong profitability is evident with a net margin of 26.81% and ROE of 82.19%, though valuation ratios like P/E of 26.15 and P/B of 21.44 appear elevated. Recent news highlights steady revenue growth and sustainability initiatives.
The outlook remains positive with a consensus price target of $217, implying significant upside, supported by 38 buy ratings and no sell recommendations. Risks include high debt levels and competitive pressures from satellite technology. The stock offers a solid dividend yield, with the next payment scheduled for July 13, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →
